Lupus & antiphospholipid syndrome
Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
Authors' conclusion
Our data suggest that systemic lupus erythematosus patients who achieve remission, both off and on-therapy, and reductions in disease activity incur lower costs than those experiencing persistent disease activity.
Study context
- Population
- SLE patients enrolled within 15 months of diagnosis, SLICC inception cohort, assessed annuallymean follow-up 9.7 years
- Participants
- 1,692 patients
- Exposure
- Proportion of time in remission/LDA states vs active disease
- Outcome
- Annual direct and indirect costs (2021 Canadian dollars) per 25% increase in time in a remission/LDA state vs active
Methodological detailsmulticentre, 31 centres in 10 countries, multivariable random-effects linear regressions
- Multicentre
- 31 centres in 10 countries
- Multivariable random-effects linear regressions
Main finding
As reported in the abstract
Annual direct/indirect costs per 25% increase in time in state vs active
- Remission off-treatment
- difference in DC -$C1372
- Remission off-treatment
- difference in IC -$C2507
- Remission on-treatment
- difference in DC -$C973
- Remission on-treatment
- difference in IC -$C2604
- LDA-TC
- difference in DC -$C1158
- Modified lupus LDA state (mLLDAS)
- difference in DC -$C1040
- Proportion of assessments active
- 49.0%
Observational data: associations, not effects.
Original publication
Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →